Transaction overview
On March 6, 2026, Derek M. Meisner, Chief Legal Officer of Acumen Pharmaceuticals (NASDAQ: ABOS), sold 2,090 shares of the company's common stock at $3.26 per share, producing proceeds of $6,813. The sale was processed automatically under a pre-arranged Rule 10b5-1 trading plan.
That same day, Meisner exercised employee stock options to acquire 2,090 additional shares at an exercise price of $1.85 per share, representing a cash outlay of $3,866. The source of those options is an employee stock option plan with awards that vest in monthly installments.
Holdings after transactions
Following the sale and the option exercise, Meisner directly owns 173,999 shares of Acumen Pharmaceuticals common stock and retains options covering 71,048 shares.
Market context reported
The transactions took place as ABOS shares trade close to a 52-week high of $3.50. The stock has delivered a 165% return over the past year, as reported alongside the transaction details.
What the record shows
- Sale: 2,090 shares sold on March 6, 2026 at $3.26, totaling $6,813. Executed under a Rule 10b5-1 plan.
- Option exercise: 2,090 options exercised at $1.85 per share, totaling $3,866. Options originated from an employee stock option plan and vest monthly.
- Post-transaction holdings: 173,999 shares directly owned; 71,048 shares covered by outstanding options.
- Share-price context: trading near a 52-week high of $3.50 and up 165% over the past year.
Limitations in the public record
The public filing and the transaction notice specify the mechanics and timing of the sale and the option exercise but do not provide additional commentary on intent beyond noting the sale was carried out under a pre-arranged Rule 10b5-1 plan. The record also confirms the options vest on a monthly schedule but does not elaborate on the vesting timeline beyond that structure.
Summary conclusion
Documents show an automatic sale of shares by Acumen Pharmaceuticals' Chief Legal Officer on March 6, 2026, paired with an option exercise on the same day. The company's share price context and Meisner's remaining direct and option-based holdings are detailed above.